STAT1 and breast cancer: These results suggested that mutations in the early stage and the downregulation of miR-145 cooperatively contributed to the core mechanism of IFN-STAT1/2-mediated bladder tumorigenesis and also that miR-145 is the key targetable gene to treat early BC (Figure 3H).